
The incidence of C. difficile colonization (CDC) after Vedolizumab (VDZ) treatment in IBD patients was 6.2%. Age >40 years and ulcerative colitis (UC) were identified as significant risk factors. A total of 454 patients were analyzed, with 28 developing CDC, including 23 with ulcerative colitis. The incidence of C. difficile infection (CDI) was 1.1%, and all patients continued VDZ treatment post-antibiotic therapy.
Like
Save
Share